No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin

Ítems similars

• Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study
  per: Frey, Reiner, et al.
  Publicat: (2016)
• Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  per: Frey, Reiner, et al.
  Publicat: (2009)
• Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality
  per: Becker, Corina, et al.
  Publicat: (2016)
• Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  per: Frey, Reiner, et al.
  Publicat: (2016)
• Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  per: Frey, Reiner, et al.
  Publicat: (2016)